Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion Of Enrollment In Phase 3 RINGSIDE Study For AL102 In Desmoid Tumors

Author: Benzinga Newsdesk | February 20, 2024 09:17am

– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month –

Posted In: ADXS IMNM